Retraction to: Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial (Gynecological Endocrinology, (2017), 33, 6, (442-447), 10.1080/09513590.2017.1290071);Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

Gynecological Endocrinology

Volumn 33, Issue 6, 2017, Pages 442-447

  Jamilian, Hamidreza ^a   Jamilian, Mehri ^b   Samimi, Mansooreh ^c   Afshar Ebrahimi, Faraneh ^c   Rahimi, Maryam ^d   Bahmani, Fereshteh ^c   Aghababayan, Sama ^c   Kouhi, Mobina ^c   Shahabbaspour, Sedighe ^c   Asemi, Zatollah ^c  

^a ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carnititine; mental health; oxidative stress; polycystic ovary syndrome

Indexed keywords

CARNITINE; GLUTATHIONE; MALONALDEHYDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ABSENCE OF SIDE EFFECTS; ADULT; AGE; ANTIOXIDANT ASSAY; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DEPRESSION; DEPRESSION ANXIETY STRESS SCALE; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENERAL HEALTH QUESTIONNAIRE; HEIGHT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MENTAL HEALTH; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL DISABILITY; SPECTROPHOTOMETRY; SUPPLEMENTATION; TREATMENT DURATION; WOMEN'S HEALTH; DIETARY SUPPLEMENT; DRUG EFFECTS; METABOLISM; PSYCHOLOGY; YOUNG ADULT;

ADULT; CARNITINE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 85013449830     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590.2024.2373613     Document Type: Erratum

References (50)

1. Greenwood EA, Pasch LA, Shinkai K, et al. Putative role for insulin resistance in depression risk in polycystic ovary syndrome. Fertil Steril 2015;104:707–14e1
2. Rahiminejad ME, Moaddab A, Rabiee S, et al. The relationship between clinicobiochemical markers and depression in women with polycystic ovary syndrome. Iran J Reprod Med 2014;12:811–6
3. Annagur BB, Kerimoglu OS, Tazegul A, et al. Psychiatric comorbidity in women with polycystic ovary syndrome. J Obstet Gynaecol Res 2015;41:1229–33
4. Klimczak D, Szlendak-Sauer K, Radowicki S., Depression in relation to biochemical parameters and age in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2015;184:43–7
5. Hahn S, Janssen OE, Tan S, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005;153:853–60
6. Gonzalez F, Rote NS, Minium J, et al. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:336–40
7. Duleba AJ, Foyouzi N, Karaca M, et al. Proliferation of ovarian theca-interstitial cells is modulated by antioxidants and oxidative stress. Hum Reprod 2004;19:1519–24
8. Youn JY, Siu KL, Lob HE, et al. Role of vascular oxidative stress in obesity and metabolic syndrome. Diabetes 2014;63:2344–55
9. Bortolato B, Miskowiak KW, Kohler CA, et al. Cognitive remission:a novel objective for the treatment of major depression? BMC Med 2016;14:9
10. Wang SM, Han C, Lee SJ, et al. A review of current evidence for acetyl-l-carnitine in the treatment of depression. J Psychiatr Res 2014;53:30–7
11. Malaguarnera M, Vacante M, Motta M, et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy:a randomized and controlled clinical trial. Metab Brain Dis 2011;26:281–9
12. Montgomery SA, Thal LJ, Amrein R., Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol 2003;18:61–71
13. Dokmeci D, Akpolat M, Aydogdu N, et al. L-carnitine inhibits ethanol-induced gastric mucosal injury in rats. Pharmacol Rep 2005;57:481–8
14. Malaguarnera M, Vacante M, Avitabile T, et al. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr 2009;89:71–6
15. Lee BJ, Lin JS, Lin YC, et al. Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease:a randomized, placebo-controlled trial. Nutr J 2014;13:79
16. Malek Mahdavi A, Mahdavi R, Kolahi S, et al. L-Carnitine supplementation improved clinical status without changing oxidative stress and lipid profile in women with knee osteoarthritis. Nutr Res 2015;35:707–15
17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
18. Huang A, Brennan K, Azziz R., Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril 2010;93:1938–41
19. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71
20. Goldberg DP, Hillier VF., A scaled version of the General Health Questionnaire. Psychol Med 1979;9:139–45
21. Crawford JR, Henry JD., The positive and negative affect schedule (PANAS):construct validity, measurement properties and normative data in a large non-clinical sample. Br J Clin Psychol 2004;43:245–65
22. Benzie IF, Strain JJ., The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”:the FRAP assay. Anal Biochem 1996;239:70–6
23. Beutler E, Gelbart T., Plasma glutathione in health and in patients with malignant disease. J Lab Clin Med 1985;105:581–4
24. Janero DR., Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990;9:515–40
25. Malaguarnera M, Bella R, Vacante M, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 2011;46:750–9
26. Samimi M, Jamilian M, Ebrahimi FA, et al. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome:a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2016;84:851–7
27. Asemi Z, Samimi M, Tabassi Z, et al. Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome:a randomized clinical trial. Nutrition 2014;30:1287–93
28. Jamilian M, Razavi M, Fakhrie Kashan Z, et al. Metabolic response to selenium supplementation in women with polycystic ovary syndrome:a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2015;82:885–91
29. Traina G., The neurobiology of acetyl-L-carnitine. Front Biosci (Landmark Ed) 2016;21:1314–29
30. Malaguarnera M., Carnitine derivatives:clinical usefulness. Curr Opin Gastroenterol 2012;28:166–76
31. Malaguarnera G, Pennisi M, Gagliano C, et al. Acetyl-L-carnitine supplementation during HCV therapy with PEGylated interferon-alpha 2b plus ribavirin:effect on work performance; a randomized clinical trial. Hepat Mon 2014;14:e11608
32. Malaguarnera M, Vacante M, Bertino G, et al. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. J Interferon Cytokine Res 2011;31:653–9
33. Cuturic M, Abramson RK, Breen RJ, et al. Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia:a cross-sectional study. World J Biol Psychiatry 2016;17:475–9
34. Cuturic M, Abramson RK, Moran RR, et al. Carnitine and metabolic correlates in hospitalized psychiatric patients:a follow-through report. J Psychiatr Pract 2011;17:35–40
35. Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:5801–7
36. Stunkard AJ, Faith MS, Allison KC., Depression and obesity. Biol Psychiatry 2003;54:330–7
37. Baischer W, Koinig G, Hartmann B, et al. Hypothalamic-pituitary-gonadal axis in depressed premenopausal women:elevated blood testosterone concentrations compared to normal controls. Psychoneuroendocrinology 1995;20:553–9
38. Rassi A, Veras AB, dos Reis M, et al. Prevalence of psychiatric disorders in patients with polycystic ovary syndrome. Compr Psychiatry 2010;51:599–602
39. Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome:clinical and biochemical correlates. J Affect Disord 2003;74:299–304
40. Genazzani AD, Chierchia E, Rattighieri E, et al. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol 2010;26:684
41. Malaguarnera M., Acetyl-L-carnitine in hepatic encephalopathy. Metab Brain Dis 2013;28:193–9
42. Tolu P, Masi F, Leggio B, et al. Effects of long-term acetyl-L-carnitine administration in rats:I. increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. Neuropsychopharmacology 2002;27:410–20
43. Cao Y, Qu HJ, Li P, et al. Single dose administration of L-carnitine improves antioxidant activities in healthy subjects. Tohoku J Exp Med 2011;224:209–13
44. Parandak K, Arazi H, Khoshkhahesh F, et al. The effect of two-week L-carnitine supplementation on exercise-induced oxidative stress and muscle damage. Asian J Sports Med 2014;5:123–8
45. Fatouros IG, Douroudos I, Panagoutsos S, et al. Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc 2010;42:1809–18
46. Gonzalez F, Nair KS, Daniels JK, et al. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab 2012;97:2836–43
47. Binienda ZK., Neuroprotective effects of L-carnitine in induced mitochondrial dysfunction. Ann N Y Acad Sci 2003;993:289–95. discussion 345-9
48. Andrieu-Abadie N, Jaffrezou JP, Hatem S, et al. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes:role of inhibition of ceramide generation. FASEB J 1999;13:1501–10
49. Yasui F, Matsugo S, Ishibashi M, et al. Effects of chronic acetyl-L-carnitine treatment on brain lipid hydroperoxide level and passive avoidance learning in senescence-accelerated mice. Neurosci Lett 2002;334:177–80
50. Kumaran S, Deepak B, Naveen B, et al. Effects of levocarnitine on mitochondrial antioxidant systems and oxidative stress in aged rats. Drugs R D 2003;4:141–7